Gene-Edited blood cells: 15-Year safety watch for thalassemia patients
NCT ID NCT06685536
Summary
This study tracks patients for up to 15 years after they received an experimental gene therapy for beta-thalassemia. Researchers want to understand the long-term safety and effectiveness of the treatment, which uses the patient's own genetically modified blood stem cells. The study follows just 5 participants who were already treated in an earlier clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Conditions
Explore the condition pages connected to this study.